First patient dosed in YK012 trial-the world’s first TCE therapy for primary membranous nephropathy
Key Highlights- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this...
